Quetiapine in Social Anxiety Disorder

This is an eight week, randomized, double-blind, placebo-controlled trial of quetiapine (100-400 mg/day)in social anxiety disorder.

Inclusion criteria

• adult outpatients 18-65 years of age
• primary diagnosis of social anxiety disorder, using DSM-IV criteria
• minimum CGI severity score of 4 at baseline
• minimum BSPS score of 20 at baseline
• written informed consent
• negative serum pregnancy test for women of childbearing potential

Exclusion criteria

• current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition
• any current primary anxiety disorder other than SAD or current primary depression
• history of substance abuse or dependence with the last 6 months
• suicide risk or serious suicide attempt within the last year
• clinically significant medical condition or laboratory abnormality
• women of childbearing potential who are unwilling to practice an acceptable method of contraception
• concomitant medication use for psychotropic purposes
• history of hypersensitivity to quetiapine